A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

NCT06664970 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

39

Enrollment

OTHER

Sponsor class

Conditions

MDS

Interventions

DRUG: Azacitidine or Ruxolitinib combined with Selinexor

Sponsor

Peking Union Medical College Hospital